PEN at a glance
Penumbra Inc (PEN, SEC CIK 1321732) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Penumbra Inc (PEN) reported revenue of $1.4 billion (up 17.5% from FY2024) and net income of $177.7 million. Diluted EPS was $4.52.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Penumbra Inc (PEN) shares worth $5.0 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.4B
- +17.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 38 funds
- $5.0B · −1 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes or new risk factors since the December 31, 2025 Form 10-K
- Carried-forward risks include regulatory approval and compliance requirements for medical devices
- Carried-forward risks include product liability, recalls, and patient safety exposure
- Carried-forward risks include competition and dependence on successful product innovation
- Carried-forward risks include manufacturing, supply-chain, and component availability disruptions
Management Discussion & Analysis
- Revenue $410.1M, up 15.6% YoY from $354.7M
- Thrombectomy strongest segment, $279.2M, up 18.1%; embolization and access $131.0M, up 10.8%
- Gross margin 68.3% vs 67.8%; operating margin 12.4% vs 13.8%; net margin 10.3% vs 12.9%
- Cash $254.3M vs $186.9M at December 31, 2025; marketable investments $419.3M vs $357.9M
- Nine-month operating cash flow $174.6M; capital expenditures $42.3M, including Costa Rica facility construction
- Near-term outlook: merger expected early 2027; Costa Rica project cost increased approximately $31M; continued product, manufacturing and international investment
AI summary of the PEN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results released October 29, 2026, covering quarter ended September 30, 2026
- Financial figures and management commentary contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- Q3 revenue $410.1M, up 15.6%, led by thrombectomy growth of 18.1% to $279.2M
- U.S. revenue growth 17.9% outpaced international growth 7.8%, highlighting domestic concentration
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Penumbra’s earnings press release furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $390.0M, up 14.9%, with U.S. growth 17.1% outpacing international growth 7.6%
- Embolization and Access revenue $131.1M, up 20.0%, outpacing thrombectomy revenue growth of 12.5%
AI summaries of PEN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PEN
Don't miss the next PEN filing
- Alerts as it files. A push when PEN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PEN, by share count.
- Ask anything. An AI agent that reads every PEN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shiu Lambert | A | Nov 16, 2026 | 3,120 | - |
| Roberts Johanna | A | Nov 16, 2026 | 3,120 | - |
| Yuen Maggie | A | Nov 16, 2026 | 3,120 | - |
| Shiu Lambert | F | Nov 15, 2026 | 830 | $320.91 |
| Yuen Maggie | F | Nov 15, 2026 | 784 | $320.91 |
| Roberts Johanna | F | Nov 15, 2026 | 1,002 | $320.91 |
| Narayan Shruthi | F | Oct 15, 2026 | 1,367 | $321.20 |
| Narayan Shruthi | F | Sep 15, 2026 | 1,230 | $318.43 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.2B | $1.4B |
| Gross Profit | - | $755.0M | $942.4M |
| Operating Income | - | $9.3M | $189.2M |
| Net Income | - | $14.0M | $177.7M |
| Gross Margin | - | 63.2% | 67.1% |
| Op. Margin | - | 0.8% | 13.5% |
| Net Margin | - | 1.2% | 12.7% |
| Balance Sheet | |||
| Total Assets | $1.6B | $1.5B | $1.8B |
| Equity | $1.2B | $1.2B | $1.4B |
| ROE | - | 1.2% | 12.4% |
| Per Share | |||
| EPS | - | $0.36 | $4.52 |
| Cash Flow | |||
| Operating CF | - | $168.5M | $238.7M |
| CapEx | - | $21.2M | $63.7M |
Source: XBRL data in Penumbra Inc (PEN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PEN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $5.02B |
| Q2 2026 | 39 | $4.94B |
| Q1 2026 | 40 | $5.04B |
| Q4 2025 | 34 | $6.80B |
| Q3 2025 | 34 | $5.98B |
| Q2 2025 | 35 | $5.42B |
| Q1 2025 | 30 | $4.01B |
| Q4 2024 | 25 | $3.16B |
- JPMorgan Chase & Co+365.1K (+34%)
- Millennium Management+338.4K (+48%)
- Goldman Sachs Group+322.9K (+38%)
- Citigroup+51.5K (+12%)
- BlackRock+2.7K (+0%)
- Citadel Advisors LLC−196.1K (-44%)
- Invesco Ltd−194.4K (-74%)
- Two Sigma Investments−99.2K (-23%)
- Bank of America Corp−82.9K (-31%)
- D.E. Shaw & Co−50.6K (-26%)
- StoneX Group Inc.+1.1K
- Marex Group plc+1.0K
- FMR LLC (Fidelity)−211.0K
- Truist Financial−1.0K
- Equitable Holdings Inc−1.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 275 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PEN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jun 22, 2026 | - | - | - |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 7, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | - | |
| 8-K | May 6, 2026 | - | - | |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 10-K | Feb 25, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 25, 2026 | - | Analysis | - |
| 4 | Feb 18, 2026 | - | - | |
| 4 | Feb 18, 2026 | - | - | |
| 4 | Feb 18, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
PEN SEC filings: frequently asked questions
Which institutions hold PEN stock?
As of September 30, 2026, the largest Penumbra Inc (PEN) holders among the 13F filers tracked by SignalX were BlackRock ($1.4 billion), Vanguard Capital Management LLC ($542.6 million), Vanguard Portfolio Management LLC ($520.3 million), JPMorgan Chase & Co ($458.8 million), State Street Corp ($393.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PEN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Penumbra Inc (PEN) reported revenue of $1.4 billion (up 17.5% from FY2024) and net income of $177.7 million. Diluted EPS was $4.52. The figures come from the XBRL data in the 10-K.
What did PEN report in its latest 8-K?
Penumbra Inc (PEN) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results released October 29, 2026, covering quarter ended September 30, 2026.
What are the latest PEN SEC filings?
Penumbra Inc (PEN) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.
What is PEN's SEC CIK number?
Penumbra Inc (PEN)'s SEC Central Index Key (CIK) is 1321732. EDGAR lists every PEN filing under that number.
Ask anything about PEN
The research agent reads PEN's filings, financials, insider trades and 13F holders, then answers with sources.